HUE047973T2 - Mezoporózus szilíciumdioxid készítmények immunválaszok modulálására - Google Patents

Mezoporózus szilíciumdioxid készítmények immunválaszok modulálására

Info

Publication number
HUE047973T2
HUE047973T2 HUE13718760A HUE13718760A HUE047973T2 HU E047973 T2 HUE047973 T2 HU E047973T2 HU E13718760 A HUE13718760 A HU E13718760A HU E13718760 A HUE13718760 A HU E13718760A HU E047973 T2 HUE047973 T2 HU E047973T2
Authority
HU
Hungary
Prior art keywords
immune responses
mesoporous silica
modulating immune
silica compositions
compositions
Prior art date
Application number
HUE13718760A
Other languages
English (en)
Inventor
Jaeyun Kim
Weiwei Aileen Li
David Mooney
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of HUE047973T2 publication Critical patent/HUE047973T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HUE13718760A 2012-04-16 2013-04-16 Mezoporózus szilíciumdioxid készítmények immunválaszok modulálására HUE047973T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261624568P 2012-04-16 2012-04-16

Publications (1)

Publication Number Publication Date
HUE047973T2 true HUE047973T2 (hu) 2020-05-28

Family

ID=48184539

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13718760A HUE047973T2 (hu) 2012-04-16 2013-04-16 Mezoporózus szilíciumdioxid készítmények immunválaszok modulálására

Country Status (17)

Country Link
US (3) US9937249B2 (hu)
EP (2) EP2838515B1 (hu)
JP (5) JP6199957B2 (hu)
CN (2) CN104244929B (hu)
AU (2) AU2013249366B2 (hu)
CA (1) CA2870309C (hu)
CY (1) CY1122699T1 (hu)
DK (1) DK2838515T3 (hu)
ES (1) ES2773895T3 (hu)
HK (1) HK1207320A1 (hu)
HR (1) HRP20200239T1 (hu)
HU (1) HUE047973T2 (hu)
LT (1) LT2838515T (hu)
PL (1) PL2838515T3 (hu)
PT (1) PT2838515T (hu)
SI (1) SI2838515T1 (hu)
WO (1) WO2013158673A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347774B1 (en) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Scaffolds for cell transplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
WO2009102465A2 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College ENHANCEMENT OF SKELETAL MUSCLE STRAIN CELL GRAFT WITH DUAL DELIVERY OF VEGF AND IGF-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
SI2624873T1 (sl) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CA2838125A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
JP6787789B2 (ja) 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
CN104127886A (zh) * 2014-07-16 2014-11-05 上海理工大学 一种CpG核酸药物输送系统及其制备方法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
SG11201804597TA (en) 2015-12-04 2018-06-28 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115305229A (zh) 2016-07-13 2022-11-08 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
JP7274214B2 (ja) * 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫応答を調節するための生体材料
US20200101010A1 (en) * 2017-05-30 2020-04-02 Theaprin Pharmaceuticals, Inc. Sublingual formulation with water-soluble cocrystals of acetylsalicylic acid with citric acid, sodium bicarbonate, and l-theanine for the treatment of acute myocardial infarction
MX2021010150A (es) 2019-02-25 2021-09-14 Novartis Ag Composiciones de particulas de silice mesoporosa para administracion viral.
CN111658767B (zh) * 2019-06-13 2022-03-22 四川大学 一种亲水性抗原和/或疏水性抗原疫苗递送系统及其制备方法
US20230138721A1 (en) * 2020-03-30 2023-05-04 Unm Rainforest Innovations Mesoporous silica nanoparticles, methods of making, and methods of using
EP4199960A2 (en) 2020-08-21 2023-06-28 Novartis AG Compositions and methods for in vivo generation of car expressing cells
US20230181644A1 (en) 2021-10-28 2023-06-15 Lyell Immunopharma, Inc. Methods of generating cells

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
GB9206504D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges as wound implants
WO1995016464A1 (en) 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
US5885829A (en) 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
ATE413415T1 (de) 1996-09-19 2008-11-15 Univ Michigan Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
US5863551A (en) 1996-10-16 1999-01-26 Organogel Canada Ltee Implantable polymer hydrogel for therapeutic uses
GB2318577B (en) 1996-10-28 2000-02-02 Johnson & Johnson Medical Solvent dried polysaccharide sponges
GB2323282B (en) 1997-03-17 2001-03-07 Bristol Myers Squibb Co Improvements relating to hygiene and medical products
EP0991705B1 (en) 1997-03-31 2003-09-10 The Regents Of The University Of Michigan Open pore biodegradable matrices
CA2291718A1 (en) 1997-05-30 1998-12-03 Osteobiologics, Inc. Fiber-reinforced, porous, biodegradable implant device
ATE345139T1 (de) 1997-08-21 2006-12-15 Takara Bio Inc Karzinostatische wirkstoffe
HU222543B1 (hu) 1998-02-23 2003-08-28 Massachusetts Institute Of Technology Biológiai úton lebomlani képes emlékező polimerek
BR9908466A (pt) 1998-03-02 2000-12-05 Applied Vaccine Technologies C Proceso para modular a resposta imune, em um mamìfero, a um antìgeno, dispositivo inplantável para modular uma resposta imune a um antìgeno, e, processos para obter células imunes de um mamìfero, para imunização de um mamìfero com um antìgeno, para a produção de hibridomas produzindo anticorpos monoclonais humanos contra um antìgeno pré-selecionado, para transfectar células imunes de um mamìfero com material genético, e para o tratamento ou profilaxia de uma doença ou condição causada por uma resposta imune
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3552099A (en) 1998-04-09 1999-11-01 Charlotte-Mecklenburg Hospital Authority Creation of three-dimensional tissues
US7427602B1 (en) 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
US7244714B1 (en) 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
FR2780730B1 (fr) 1998-07-01 2000-10-13 Corneal Ind Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
AU766826B2 (en) 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
CA2346329A1 (en) 1998-10-09 2000-04-20 Kamal H. Bouhadir Hydrogels and water soluble polymeric carriers for drug delivery
CN100558401C (zh) * 1998-10-16 2009-11-11 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6974698B1 (en) 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
ES2199815T3 (es) 1999-03-19 2004-03-01 The Regents Of The University Of Michigan Mineralizacion y desarrollo celular supeerficial sobre biomateriales.
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
DK1163019T3 (da) 1999-03-25 2008-03-03 Metabolix Inc Medicinske indretninger og anvendelser af polyhydroxyalkanoatpolymere
EP1169378A4 (en) 1999-04-09 2004-06-02 Univ Michigan PREPARATION OF PRODUCTS BASED ON HYDROGEL
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
AU782297B2 (en) 1999-06-30 2005-07-14 Ethicon Inc. Porous tissue scaffoldings for the repair or regeneration of tissue
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
EP1206254A1 (en) 1999-08-06 2002-05-22 The Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
AU1622801A (en) 1999-11-18 2001-05-30 Regents Of The University Of Michigan, The Sustained drug delivery from structural matrices
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6790840B1 (en) 1999-11-26 2004-09-14 The Regents Of The University Of Michigan Reversibly cross-linked hydrogels
WO2002009650A2 (en) 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1311657A2 (en) 2000-08-21 2003-05-21 Rice University Tissue engineering scaffolds promoting matrix protein production
US7785810B2 (en) 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6748954B2 (en) 2000-10-27 2004-06-15 The Regents Of The University Of Michigan Drug release from polymer matrices through mechanical stimulation
JPWO2002040071A1 (ja) 2000-11-14 2004-03-18 上田　実 骨又は歯周組織形成用組成物、及び骨又は歯周組織形成用注射剤
WO2002041913A1 (en) 2000-11-27 2002-05-30 Jens Christian Jensenius Collectins as adjuvants
US20070198739A1 (en) 2001-01-19 2007-08-23 Streamworks Technologies, Inc. System and method for routing media
MXPA03006587A (es) 2001-01-24 2003-09-22 Schering Corp Quimiocinas como adyuvantes de respuesta inmune.
US7029697B2 (en) 2001-02-14 2006-04-18 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
WO2002068605A2 (en) 2001-02-26 2002-09-06 The Regents Of The University Of California Non-oligomerizing tandem fluorescent proteins
US20020131953A1 (en) 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
JP2002263981A (ja) 2001-03-14 2002-09-17 Murata Mach Ltd 板材吸着持ち上げ装置の吸着制御装置
US6656488B2 (en) 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
CN1541113A (zh) 2001-04-27 2004-10-27 �Ƹ��� 利用激活的t细胞使抗原提呈细胞成熟
US20030118630A1 (en) 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
CA2447030C (en) 2001-05-11 2010-07-13 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
EP1407261A4 (en) 2001-06-13 2006-11-22 Massachusetts Inst Technology BIOREACTORS FOR IN VIVO REACTIONS
US7297343B2 (en) 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
AU2002361902A1 (en) 2001-12-31 2003-07-24 Ares Medical, Inc. Hemostatic compositions and methods for controlling bleeding
US7575759B2 (en) 2002-01-02 2009-08-18 The Regents Of The University Of Michigan Tissue engineering scaffolds
US20050220773A1 (en) 2002-02-19 2005-10-06 Toshimasa Uemura Implant containing cells having growhfactor gene transferred thereinto
US20080233181A1 (en) 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
US6811777B2 (en) 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
WO2003089506A1 (en) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
WO2003089642A1 (en) 2002-04-22 2003-10-30 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
US20040242469A1 (en) 2002-05-13 2004-12-02 Lee Richard T. Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7332160B2 (en) 2002-07-12 2008-02-19 Boston Scientific Scimed, Inc. Medical device and method for tissue removal and repair
ES2375299T3 (es) 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
US20040136968A1 (en) 2002-09-27 2004-07-15 Verigen Ag Autologous cells on a support matrix for tissue repair
US20040063206A1 (en) 2002-09-30 2004-04-01 Rowley Jon A. Programmable scaffold and method for making and using the same
AU2003272805A1 (en) 2002-10-01 2004-04-23 Peter K. Law Bioactive implants
JP2004159849A (ja) 2002-11-12 2004-06-10 National Institute Of Advanced Industrial & Technology 細胞接着性生体吸収材料、人工血管およびそれらの製造方法
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US8940292B2 (en) 2003-01-28 2015-01-27 Wake Forest University Health Sciences Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
EP1620140B1 (en) 2003-05-05 2013-10-09 Ben-Gurion University Of The Negev Research And Development Authority Injectable cross-linked polymeric preparations and uses thereof
EP1475434A1 (en) 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
JP2007528848A (ja) 2003-07-09 2007-10-18 ヴァックスデザイン・コーポレーション ワクチン接種ノードを用いるプログラムされた免疫応答
US20060264380A1 (en) 2003-07-21 2006-11-23 Mats Hellstrom Compounds and Methods for Promoting Angiogenesis
GB0317999D0 (en) 2003-07-31 2003-09-03 Univ Liege Improvements in or relating to drug delivery systems
JP2007500721A (ja) 2003-07-31 2007-01-18 エンダセア，インク． 抗原応答を生じさせる方法及び組成物
US20080206308A1 (en) 2003-08-29 2008-08-28 Esmaiel Jabbari Hydrogel Porogents for Fabricating Biodegradable Scaffolds
WO2005037190A2 (en) 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2004281080A1 (en) 2003-10-16 2005-04-28 Stephen John Ralph Immunomodulating compositions and uses therefor
WO2005046461A1 (en) 2003-11-07 2005-05-26 Carnegie Mellon University Robot for minimally invasive interventions
CA2448995A1 (en) 2003-11-12 2005-05-12 James Keenan Device and method for attracting diseased cells and foreign substances
JP2005160669A (ja) 2003-12-02 2005-06-23 Olympus Corp 生体組織補填体の製造方法
JP2005170816A (ja) 2003-12-09 2005-06-30 Naoki Ishiguro 軟骨修復用材料、およびその製造方法
JP2005168760A (ja) 2003-12-10 2005-06-30 Gunze Ltd 再生医療用支持体、血管再生用支持体、神経再生用支持体及び治療方法
WO2005072088A2 (en) 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US7192693B2 (en) 2004-02-24 2007-03-20 University Of Washington Methods for photopatterning hydrogels
EP1729781B1 (en) 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
AU2005237588B2 (en) 2004-04-28 2010-07-08 Massachusetts Institute Of Technology Artificial immune system: methods for making and use
WO2006080946A2 (en) 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US8080245B2 (en) 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
WO2006039045A2 (en) 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
CA2583373C (en) 2004-10-12 2013-09-03 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
US7999161B2 (en) 2005-01-22 2011-08-16 Alexander Oraevsky Laser-activated nanothermolysis of cells
US7569850B2 (en) 2005-01-24 2009-08-04 Lawrence Livermore National Security, Llc Lipid bilayers on nano-templates
AU2006226923B2 (en) 2005-03-23 2011-10-13 Mayo Foundation For Medical Education And Research Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery
WO2006105278A2 (en) 2005-03-29 2006-10-05 The Regents Of The University Of California Controlling stem cell destiny destiny with tunable network
EP1712238A1 (en) 2005-04-11 2006-10-18 Institut Gustave Roussy Anthracyclin induced immunogenic dead or dying cells composition
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20070003595A1 (en) 2005-04-19 2007-01-04 Shaopeng Wang Three dimensional micro-environments and methods of making and using same
WO2006116423A2 (en) 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
ITPI20050071A1 (it) 2005-06-20 2006-12-21 Giuseppe Calvosa Composizione biocompatibile per la sostituzione/rigenerazione di tessuti
US7645742B2 (en) 2005-06-22 2010-01-12 Advocare International, L.P. Composition for enhancing cellular energy
CN1302050C (zh) 2005-07-07 2007-02-28 复旦大学 一种互穿网络聚合物超多孔水凝胶及其制备方法和应用
WO2007022188A2 (en) 2005-08-15 2007-02-22 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery A porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
EP3184631B1 (en) 2005-09-23 2020-08-12 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US20070081972A1 (en) 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
CA2625488A1 (en) 2005-10-12 2007-04-19 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
US8029575B2 (en) 2005-10-25 2011-10-04 Globus Medical, Inc. Porous and nonporous materials for tissue grafting and repair
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
WO2007063075A1 (en) 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens
KR100687281B1 (ko) 2005-11-30 2007-02-27 한국과학기술연구원 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법
PL1957044T3 (pl) 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
EP2347774B1 (en) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Scaffolds for cell transplantation
AU2015264807A1 (en) 2005-12-13 2015-12-17 President And Fellows Of Harvard College Scaffolds for Cell Transplantation
EP1960008A2 (en) 2005-12-14 2008-08-27 Scil Technology GmbH A moldable biomaterial for bone regeneration
EP1806395A1 (en) 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20070178159A1 (en) 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
JP2009525341A (ja) 2006-01-31 2009-07-09 メディバス エルエルシー ワクチン送達組成物および使用法
US20070190646A1 (en) 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
US20090041825A1 (en) 2006-02-10 2009-02-12 Kotov Nicholas A Cell culture well-plates having inverted colloidal crystal scaffolds
US20100015709A1 (en) 2006-02-10 2010-01-21 Trustees Of The University Of Pennsylvania Regulating Stem Cell Differentiation By Controlling 2D and 3D Matrix Elasticity
CN101405037A (zh) 2006-02-27 2009-04-08 新加坡科技研究局 可固化骨粘固剂
US9456860B2 (en) 2006-03-14 2016-10-04 Kci Licensing, Inc. Bioresorbable foaming tissue dressing
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
WO2008127256A1 (en) 2006-06-01 2008-10-23 Massachusetts Institute Of Technology Control of cells and cell multipotentiality in three dimensional matrices
WO2007146319A2 (en) 2006-06-13 2007-12-21 Symphony Medical, Inc. Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications
US20070298067A1 (en) 2006-06-22 2007-12-27 Boston Scientific Scimed, Inc. Control release drug coating for medical devices
US8318912B2 (en) 2006-06-23 2012-11-27 Augmenta Biologicals, Llc Targeted immune conjugate comprising an antibody to glycophorin A and a M2e peptide
WO2008008266A2 (en) 2006-07-07 2008-01-17 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Biohybrid elastomeric scaffolds and methods of use thereof
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
KR100802139B1 (ko) 2006-08-08 2008-02-11 한국생명공학연구원 자성 나노입자를 함유하는 골드 나노케이지
KR100818708B1 (ko) 2006-08-18 2008-04-01 주식회사 하이닉스반도체 표면 세정을 포함하는 반도체소자 제조방법
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
GB2455041B (en) 2006-09-21 2012-03-07 Purdue Research Foundation Collagen preparation and method of isolation
EP2077821B1 (en) 2006-10-12 2019-08-14 The University Of Queensland Compositions and methods for modulating immune responses
JP5850516B2 (ja) 2006-11-09 2016-02-03 ケーシーアイ ライセンシング インコーポレイテッド 創傷に快適なポーラス状生体再吸収性ドレッシング及びその製造方法
US8709464B2 (en) 2007-01-10 2014-04-29 The Regents Of The University Of Michigan Porous objects having immobilized encapsulated biomolecules
EP3269384A1 (en) 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
US8501905B2 (en) 2007-03-22 2013-08-06 The Regents Of The University Of California Synthetic cell platforms and methods of use thereof
EP1975230A1 (en) 2007-03-30 2008-10-01 Capsulution Nanoscience AG Method for forming glucose sensing micro-particles, use of micro-particles, and kit
WO2008131074A1 (en) 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
MX2009013220A (es) 2007-06-05 2010-04-09 Novartis Ag Induccion de fenotipo tolerogenico en las celulas dendriticas maduras.
WO2008157394A2 (en) 2007-06-13 2008-12-24 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
DK2173859T3 (en) 2007-06-29 2016-08-22 Makoto Funaki Soft-gel systems for the modulation of stem cell development
CA2695385A1 (en) 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
GB0716264D0 (en) 2007-08-21 2007-09-26 Isis Innovation Bilayers
US20090192079A1 (en) 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009102465A2 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
WO2009117721A1 (en) 2008-03-21 2009-09-24 3D Biotek, Llc Hybrid biomedical device fabricated from biomaterials and coated with a cell culture derived ecm coating
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US20110182957A1 (en) 2008-06-19 2011-07-28 Nicoll Steven B Cellulosics for tissue replacement
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
US8889124B2 (en) 2008-09-25 2014-11-18 The Board Of Trustees Of The Leland Stanford Junior University Tolerogenic populations of dendritic cells
US8940331B2 (en) 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
KR101132732B1 (ko) 2008-11-26 2012-04-06 한국과학기술연구원 인 시튜 조직재생용 지능형 다공성 생분해 고분자 지지체 및 이의 제조방법
US8273373B2 (en) 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
US9139809B2 (en) * 2009-01-08 2015-09-22 Albert Einstein College Of Medicine Of Yeshiva University Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
JP2010227012A (ja) 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞捕捉デバイス
JP5273551B2 (ja) * 2009-03-27 2013-08-28 独立行政法人産業技術総合研究所 繊維状多孔質シリカ粒子の製造方法
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8551749B2 (en) 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
CN101655611B (zh) 2009-09-11 2011-06-08 中国科学院长春应用化学研究所 一种具有双层杂化结构的反蛋白石水凝胶光子晶体的制备方法
JP2013507124A (ja) 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｉｌ−２３ｒを結合するポリペプチド
CA2776954A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial libraries based on c-type lectin domain
US20110207166A1 (en) 2009-11-06 2011-08-25 Sarah Rivkah Vaiselbuh Human bone marrow microenvironments and uses thereof
EP2514718A4 (en) 2009-12-18 2013-09-04 Kao Corp METHOD FOR PRODUCING MESOPOROUS SILICONE ARTICLES
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
AU2011217780B2 (en) 2010-02-22 2016-02-11 Incredible Foods, Inc. Enclosing materials in natural transport systems
RU2012141952A (ru) 2010-03-02 2014-04-10 Кинг Абдулла Юнивесити Ов Сайенс Энд Текнолэджи Наночастицы волокон оксида кремния с развитой поверхностью
WO2011108649A1 (ja) 2010-03-04 2011-09-09 地方独立行政法人東京都立産業技術研究センター 多孔質シリカの製造方法および多孔質シリカ
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College ENHANCEMENT OF SKELETAL MUSCLE STRAIN CELL GRAFT WITH DUAL DELIVERY OF VEGF AND IGF-1
CN102905732A (zh) 2010-03-15 2013-01-30 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的方法
US20110300186A1 (en) * 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
US20110256184A1 (en) 2010-04-14 2011-10-20 Battelle Memorial Institute Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
CA2796451A1 (en) * 2010-04-16 2011-10-20 Nicholas J. Mastandrea Wearable motion sensing computing interface
CN105194665A (zh) 2010-05-26 2015-12-30 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
EP2593098A4 (en) 2010-07-16 2014-02-05 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
EP3298986A1 (en) 2010-08-04 2018-03-28 Georgia Tech Research Corporation Devices, systems, and methods for excavating cancer cells
JP2012062236A (ja) * 2010-09-17 2012-03-29 National Institute Of Advanced Industrial Science & Technology 円筒状のアルミナ細孔内における界面活性剤を鋳型としたメソポーラスシリカナノチューブの合成及びそのナノチューブ体
SI2624873T1 (sl) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
KR20140029469A (ko) 2011-04-29 2014-03-10 셀렉타 바이오사이언시즈, 인크. 세포독성 t 림프구 반응을 감소시키는 관용원성 합성 나노운반체
CA2838125A1 (en) 2011-06-03 2012-12-06 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US8609688B2 (en) 2011-06-24 2013-12-17 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US20130145488A1 (en) 2011-12-06 2013-06-06 Iowa State University Research Foundation, Inc. Mesoporous silica nanoparticles suitable for co-delivery
EP2802350B1 (en) 2012-01-13 2017-12-20 President and Fellows of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
PT2825156T (pt) 2012-03-16 2017-11-02 Merck Patent Gmbh Aminoácidos lipídicos de direcionamento
PT2838515T (pt) * 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
KR20150023811A (ko) 2012-06-21 2015-03-05 컴퓨젠 엘티디. 암의 치료를 위한 lsr 항체 및 그의 용도
US20140072510A1 (en) 2012-09-13 2014-03-13 Northwestern University Synthetic Scaffolds for Metastasis Detection
WO2014063128A1 (en) 2012-10-20 2014-04-24 Board Of Regents, The University Of Texas System Cancer cell trap
JP6646571B2 (ja) 2013-03-13 2020-02-14 クリエイティクス エルエルシー 膵臓がんを検出するための方法および組成物
MY175308A (en) 2013-05-18 2020-06-18 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3010522B1 (en) 2013-05-21 2021-01-20 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
US20160129053A1 (en) 2013-05-24 2016-05-12 President And Fellows Of Harvard College Methods of isolating microorganisms and uses thereof
AU2014342004B2 (en) 2013-11-01 2017-10-26 Yale University Modular particles for immunotherapy
WO2015077354A1 (en) 2013-11-19 2015-05-28 The University Of Chicago Use of sting agonist as cancer treatment
ES2951908T3 (es) 2014-04-04 2023-10-25 Harvard College Hidrogeles reticulados por química clic y métodos de uso
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
US11065362B2 (en) 2014-06-12 2021-07-20 President And Fellows Of Harvard College Viscoelastic hydrogels with fast stress relaxation
US11229607B2 (en) 2014-06-30 2022-01-25 President And Fellows Of Harvard College Hydrogel compositions comprising encapsulated cells and methods of use thereof
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016161372A1 (en) 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
CN117244049A (zh) 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法
CN115305229A (zh) 2016-07-13 2022-11-08 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
JP7274214B2 (ja) 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫応答を調節するための生体材料

Also Published As

Publication number Publication date
JP2019006831A (ja) 2019-01-17
SI2838515T1 (sl) 2020-07-31
JP6800195B2 (ja) 2020-12-16
JP6500061B2 (ja) 2019-04-10
US9937249B2 (en) 2018-04-10
CA2870309C (en) 2024-02-20
DK2838515T3 (da) 2020-02-24
CN107137357B (zh) 2020-11-24
AU2018202973B2 (en) 2020-06-04
JP6199957B2 (ja) 2017-09-20
US20180344821A1 (en) 2018-12-06
HK1207320A1 (en) 2016-03-24
CA2870309A1 (en) 2013-10-24
JP2022111336A (ja) 2022-07-29
EP3662896A1 (en) 2020-06-10
AU2013249366A1 (en) 2014-09-25
CN104244929B (zh) 2017-04-05
HRP20200239T1 (hr) 2020-08-21
US20230000961A1 (en) 2023-01-05
JP2018048116A (ja) 2018-03-29
AU2013249366B2 (en) 2018-02-01
LT2838515T (lt) 2020-03-10
CY1122699T1 (el) 2021-03-12
CN104244929A (zh) 2014-12-24
AU2018202973A1 (en) 2018-05-17
CN107137357A (zh) 2017-09-08
US11278604B2 (en) 2022-03-22
JP2020172542A (ja) 2020-10-22
PL2838515T3 (pl) 2020-06-29
JP2015516398A (ja) 2015-06-11
ES2773895T3 (es) 2020-07-15
WO2013158673A1 (en) 2013-10-24
US20150072009A1 (en) 2015-03-12
EP2838515A1 (en) 2015-02-25
JP7092393B2 (ja) 2022-06-28
EP3662896B1 (en) 2024-02-28
PT2838515T (pt) 2020-02-25
EP2838515B1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
HK1207320A1 (en) Mesoporous silica compositions for modulating immune responses
HK1212597A1 (zh) 用於調節 表達的組合物
EP2844756A4 (en) MODULATION OF IMMUNE REACTIONS
GB201317141D0 (en) Well Isolation
PL3153144T3 (pl) Urządzenie izolacyjne
EP2694438A4 (en) MESOPOROUS ZEOLITE WITH MODIFIED FRAME
EP2805317A4 (en) FLIGHT SIMULATOR BASED ON CENTRIFUGAL FORCE
SG11201503985SA (en) Uzm-44 aluminosilicate zeolite
AU345890S (en) Universal Light
EP2935104A4 (en) UZM-43, AN EUO NES NON-TEMPLATE
EP2889333A4 (en) MODIFIED SILICA COMPOSITION
ZA201406203B (en) Adjuvant compositions
GB201222406D0 (en) Gel compositions
HK1215197A1 (zh) 凝膠組合物
ZA201503102B (en) Finafloxacin suspension compositions
GB201222405D0 (en) Gel compositions
EP2866586A4 (en) AQUEOUS LIPID CAROTINOIDIC COMPOSITIONS
GB201222403D0 (en) Gel compositions
GB201204751D0 (en) Immune modulation
AU4709P (en) LRU30 Alternanthera dentata
GB201216953D0 (en) Glasses
GB201213898D0 (en) Milk dummies
GB201222407D0 (en) Gel compositions
GB201208476D0 (en) Compositions and methods for modulating an immune response
GB201213688D0 (en) Transformer